Intensive maintenance treatment in acute myelogenous leukemia (AML): single institution experience of a multicenter randomized trial.
Sixty-three AML patients were entered into a randomized, prospective trial to investigate the impact of intensive maintenance treatment on remission duration and survival. The maintenance program consisted of either a rotating combination of alternative drugs (HD-Ara C, mAMSA, 5-AZA) not used during induction and consolidation or, alternatively, of a repeated induction type chemotherapy early after consolidation (DNM, VCR, Ara C). In 48 out of 63 patients reaching CR, no prolongation of either remission duration or survival was achieved as compared to a preceding randomized study using conventional maintenance treatment.
Jehn
U
U
Med. Klinik III, Ludwig-Maximilians-Universität München, Klinikum Grosshadern, FRG.
Knüppel
W
W
Wilmanns
W
W
D000293:Adolescent; D000328:Adult; D000368:Aged; D000677:Amsacrine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage; D003596:Cytosine / Q000008:administration & dosage / Q000031:analogs & derivatives; D003630:Daunorubicin / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008875:Middle Aged; D011897:Random Allocation; D014750:Vincristine / Q000008:administration & dosage
D000677:Amsacrine; D003561:Cytarabine; C039854:5-azacytosine; D014750:Vincristine; D003596:Cytosine; D003630:Daunorubicin